---
url: https://www.servicesaustralia.gov.au/lymphoma-systemic-anaplastic-large-cell-lymphoma
title: Lymphoma - systemic anaplastic large cell lymphoma - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:14.889Z
source: servicesaustralia.gov.au
---
# Lymphoma - systemic anaplastic large cell lymphoma

The PBS subsidises brentuximab vedotin for patients with CD30 positive systemic anaplastic large cell lymphoma (sALCL).

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with brentuximab vedotin under the _National Health Act 1953_, section 100 for patients with CD30 positive sALCL.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing brentuximab vedotin.

## Section 100 arrangements

This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending:

-   an approved private hospital
-   a public participating hospital
-   a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised brentuximab vedotin to treat CD30 positive sALCL can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include the completed:

-   authority prescription form or forms
-   [CD30 positive systemic anaplastic large cell lymphoma - brentuximab vedotin - initial authority application form](/pb123?context=20)
-   relevant attachments.

### Continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised brentuximab vedotin to treat CD30 positive sALCL can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
